Location History:
- Camarillo, CA (US) (2006 - 2011)
- Scotts Valley, CA (US) (2012)
Company Filing History:
Years Active: 2006-2012
Title: Marco A Coccia: Innovator in Monoclonal Antibodies and Blood Disorder Treatments
Introduction
Marco A Coccia is a notable inventor based in Camarillo, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies and treatments for blood disorders. With a total of 3 patents, his work has the potential to impact various medical conditions.
Latest Patents
Coccia's latest patents include groundbreaking innovations such as "Human monoclonal antibodies to CD70." This patent provides isolated monoclonal antibodies that specifically bind to CD70 with high affinity. It also includes nucleic acid molecules encoding these antibodies, expression vectors, host cells, and methods for expressing the antibodies. Furthermore, it outlines immunoconjugates, bispecific molecules, and pharmaceutical compositions that incorporate these antibodies. The patent also details methods for treating cancer, autoimmune diseases, inflammation, and viral infections. Another significant patent is the "Method of treating anemia by administering IL-1ra." This invention relates to methods of treating blood disorders in mammals using an interleukin-1 (IL-1) inhibitor, along with compositions that combine IL-1 inhibitors with TNF inhibitors and erythropoietin (EPO) receptor agonists.
Career Highlights
Throughout his career, Marco A Coccia has worked with prominent companies in the biotechnology sector, including Amgen Inc. and Medarex Inc. His experience in these organizations has contributed to his expertise in developing innovative medical treatments.
Collaborations
Coccia has collaborated with notable professionals in his field, including Jonathan Kay and Dorothy McCabe. These collaborations have likely enhanced his research and development efforts.
Conclusion
Marco A Coccia is a distinguished inventor whose work in monoclonal antibodies and blood disorder treatments showcases his commitment to advancing medical science. His patents reflect a dedication to improving patient outcomes and addressing critical health challenges.